Mirabo and CMP Develop Automated CE-MS Antibody Platform
Mirabo Biotechnology and CMP Scientific announced today a strategic partnership to co-develop an AI-powered, automated CE-MS platform for analyzing and predicting antibody clipping variants and post-translational modifications. The collaboration will deliver two interoperable software modules—CE-MS data analysis and AI prediction—plus an end-to-end detect-analyze-predict-redesign service to accelerate biologics R&D and improve critical quality attribute assessment.
Key Points
- 1Announce co-development of automated CE-MS platform for antibody clipping variants and PTMs.
- 2Combine CMP's CE-MS instrumentation expertise with Mirabo's MiRAiQ AI engines for predictive molecular analysis.
- 3Enable end-to-end detect-analyze-predict-redesign workflow, reducing manual interpretation and accelerating biologics quality assessment.
Scoring Rationale
Official partnership with concrete product plans and clear industry relevance; impact confined to the biologics analytics vertical.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
